US 11,654,298 B2
Method for treating cancerous and pre-cancerous skin
Christopher Baker, Alexandria (AU); Judith Mary Cole, Alexandria (AU); Robert Sinclair, Alexandria (AU); Warren Weightman, Alexandria (AU); Stephen Shumack, Alexandria (AU); Lynda Spelman, Alexandria (AU); and Peter Foley, Alexandria (AU)
Assigned to GenesisCare Ventures Pty Ltd, Alexandria (AU)
Filed by GenesisCare Ventures Pty Ltd, Alexandria (AU)
Filed on Jan. 7, 2022, as Appl. No. 17/570,670.
Application 17/570,670 is a continuation of application No. 17/183,654, filed on Feb. 24, 2021, granted, now 11,253,724.
Claims priority of application No. 2020902243 (AU), filed on Jul. 1, 2020; application No. PCTAU202005242 (AU), filed on Nov. 17, 2020; and application No. PCTAU2021050129 (AU), filed on Feb. 15, 2021.
Prior Publication US 2022/0126115 A1, Apr. 28, 2022
Int. Cl. A61N 5/10 (2006.01); A61K 35/00 (2006.01); A61B 17/3205 (2006.01); A61K 31/513 (2006.01); A61K 31/4439 (2006.01); A61N 5/06 (2006.01); A61P 35/00 (2006.01); A61P 17/02 (2006.01); A61B 18/02 (2006.01); A61B 17/00 (2006.01); A61N 5/067 (2006.01)
CPC A61N 5/10 (2013.01) [A61B 17/3205 (2013.01); A61K 31/4439 (2013.01); A61K 31/513 (2013.01); A61K 35/00 (2013.01); A61N 5/062 (2013.01); A61N 5/0616 (2013.01); A61P 17/02 (2018.01); A61P 35/00 (2018.01); A61B 18/0218 (2013.01); A61B 2017/00761 (2013.01); A61N 5/067 (2021.08); A61N 2005/0663 (2013.01)] 16 Claims
 
1. A method for treating clinical or pre-clinical skin damage in a skin field of a subject, wherein the skin field has been allocated a global score of at least 1 by a process comprising the steps of:
(i) assessing the skin field for:
(a) a small area affected with few or thin keratoses;
(b) patchy involvement in the zone, moderately thick keratosis, or patchy involvement in the zone with moderately thick keratoses;
(c) extensive involvement of the zone, numerous thicker keratosis, or extensive involvement of the zone with numerous thicker keratoses;
(d) extensive involvement of the zone with (A) numerous thicker keratosis with cutaneous horn; and/or (B) confluent (i.e. continuous) keratoses, or
(e) near complete involvement of the zone with numerous thicker keratosis, wherein the assessment does not involve assessment of erythema in the skin field; and
(ii) assigning the skin field a global score based on the results of assessment (i) wherein the global score assigned is 1 for (a), 2 for (b), 3 for (c) and 4 for (d) or (e);
the method for treating the clinical or pre-clinical skin damage comprising:
treating the skin field with field radiotherapy when the skin field is assigned a global score of 4;
treating the skin field with field radiotherapy and/or applying a topical treatment when the skin field is assigned a global score of 3;
A. treating the skin field by applying a topical treatment and/or lesional therapy when the skin field is assigned a global score of 2; and
B. treating the skin field with lesional therapy when the skin field is assigned a global score of 1.